0.02Open0.02Pre Close0 Volume1.45K Open Interest7.50Strike Price0.00Turnover771.89%IV1500.00%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type0.1025Delta0.2705Gamma23.51Leverage Ratio-0.0046Theta0.0000Rho2.41Eff Leverage0.0002Vega
Relmada Therapeutics Stock Discussion
Dow Jones· 5 mins ago
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder Value
Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial Is Futile at Its Interim Analysis and Is Unlikely to Meet the Primary Efficacy Endpoint With Statistical Significance
No comment yet